Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Nanoparticles As Carriers For Nasal Vaccine Delivery

M. Köping-Höggård, A. Sánchez, M. Alonso
Published 2005 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
At present, there is considerable excitement within the nanotechnology field with regard to the potential use of nanosystems as carriers for mucosal vaccine delivery. Indeed, many of the vaccines available, including protein antigens and DNA vaccines, are very unstable and need to be protected from degradation in the biologic environment. In addition, their efficacy is limited by their poor capacity to cross biologic barriers and reach the target sites. As a consequence, the design of appropriate antigen carriers that could help overcome these problems has become a significant challenge. The goal of the present article is to review the recent advances in the design of polymeric nanosystems intended to be used as carriers for nasal vaccine delivery. More specifically, the authors present nanocarriers that have been made of safe materials, such as biodegradable polyesters and polysaccharides. The information accumulated regarding the in vivo behavior of these nanocarriers indicates that they are able to facilitate the transport of the associated antigen across the nasal epithelium, thus leading to efficient antigen presentation to the immune system. Furthermore, the results suggest that not only the size and surface properties but also the polymer composition and the structural architecture of the nanosystems are critical for the optimization of these antigen carriers. In conclusion, future studies intended to provide increased knowledge regarding these properties and how they relate to the efficiency of the immune responses, will undoubtedly affect the design of new and more effective nasal vaccine delivery strategies.
This paper references
10.1016/S0264-410X(01)00471-6
Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis.
W. P. Beyer (2002)
10.1023/A:1018967116988
Effect of Chitosan on the Permeability of Monolayers of Intestinal Epithelial Cells (Caco-2)
P. Artursson (2004)
10.1023/A:1011922819926
Stealth PLA-PEG Nanoparticles as Protein Carriers for Nasal Administration
M. Tobío (2004)
• Shows for the first time the effect of the particle size and also of a polyethylene glycol (PEG) coating on the interaction and transport of nanoparticles across the nasal mucosa
10.1016/S0264-410X(00)00309-1
A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery.
E. McNeela (2000)
10.1023/A:1016104910582
Recent Advances in Vaccine Adjuvants
M. Singh (2004)
10.1016/0378-5173(92)90353-4
In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers
C. Lehr (1992)
10.1023/A:1012029517394
The Oral Absorption of Micro- and Nanoparticulates: Neither Exceptional Nor Unusual
A. Florence (2004)
10.1021/BM049577P
PLGA:poloxamer and PLGA:poloxamine blend nanoparticles: new carriers for gene delivery.
N. Csaba (2005)
10.1016/S0264-410X(99)00313-8
Improved immunogenicity of a core-coated tetanus toxoid delivery system.
M. Tobío (1999)
• Demonstrates the effect of particle size on the efficiency of modified polyester particles for mucosal immunization
10.1023/B:PHAM.0000022414.17183.58
Novel Chitosan Particles and Chitosan-Coated Emulsions Inducing Immune Response via Intranasal Vaccine Delivery
Takahiro Nagamoto (2004)
10.1007/S003960050050
Development of positively charged colloidal drug carriers: Chitosan-coated polyester nanocapsules and submicron-emulsions
P. Calvo (1997)
PLA–PEG nanoparticles as nasal drug carriers: approaches to the modulation of the PEG coating
A Vila (2003)
10.1016/S0264-410X(98)00077-2
Stimulation of mucosal and systemic antibody responses against Bordetella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice.
I. Jabbal‐Gill (1998)
10.1016/S0169-409X(01)00165-X
Immunostimulating complexes (ISCOMs) for nasal vaccination.
K. Hu (2001)
10.1016/S0168-3659(01)00397-2
Poly(lactic acid)-poly(ethylene glycol) nanoparticles as new carriers for the delivery of plasmid DNA.
C. Pérez (2001)
10.1016/J.EJPB.2003.09.006
Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice.
A. Vila (2004)
10.3748/WJG.V10.I1.112
Transfection of mEpo gene to intestinal epithelium in vivo mediated by oral delivery of chitosan-DNA nanoparticles.
J. Chen (2004)
10.1089/10430340260185058
Intranasal gene transfer by chitosan-DNA nanospheres protects BALB/c mice against acute respiratory syncytial virus infection.
M. Kumar (2002)
10.1016/S0264-410X(03)00305-0
The concomitant use of the LTK63 mucosal adjuvant and of chitosan-based delivery system enhances the immunogenicity and efficacy of intranasally administered vaccines.
B. Baudner (2003)
Controlled release of Bordetella bronchiseptica dermonecrotoxin (BBD) vaccine from BBD-loaded chitosan microspheres in vitro
H L Jiang (2004)
10.1016/J.VACCINE.2003.09.012
Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan.
E. McNeela (2004)
10.1002/jgm.327
Relationship between the physical shape and the efficiency of oligomeric chitosan as a gene delivery system in vitro and in vivo
M. Köping-Höggård (2003)
10.1023/A:1012160102740
Chitosans as Absorption Enhancers for Poorly Absorbable Drugs 2: Mechanism of Absorption Enhancement
N. G. Schipper (2004)
10.1023/A:1012128907225
Chitosan and Chitosan/Ethylene Oxide-Propylene Oxide Block Copolymer Nanoparticles as Novel Carriers for Proteins and Vaccines
P. Calvo (2004)
10.1163/1568562041753098
Design and characterisation of new nanoparticulate polymer blends for drug delivery
N. Csaba (2004)
Biocompatibility of chitosan by oral and intravenous administration
S Hirano (1989)
10.1038/sj.gt.3302312
Improved chitosan-mediated gene delivery based on easily dissociated chitosan polyplexes of highly defined chitosan oligomers
M. Köping-Höggård (2004)
10.1016/S0928-0987(99)00032-9
Chitosans as absorption enhancers of poorly absorbable drugs. 3: Influence of mucus on absorption enhancement.
N. G. Schipper (1999)
Pulsed controlled release system for potential use in vaccine
A Sanchez (1996)
10.1186/1479-0556-1-1
Genetic therapy: on the brink of a new future
G. Hellermann (2003)
10.1023/A:1011081210142
Development of Systems for Targeting the Regional Lymph Nodes for Diagnostic Imaging: In Vivo Behaviour of Colloidal PEG-Coated Magnetite Nanospheres in the Rat Following Interstitial Administration
L. Illum (2004)
Evidence for a common mucosal immunologic system. I. Migration of B immunoblasts into intestinal, respiratory, and genital tissues.
M. Mcdermott (1979)
10.1021/JS960069Y
Pulsed controlled-released system for potential use in vaccine delivery.
A. Sánchez (1996)
10.1038/7385
Oral gene delivery with chitosan–DNA nanoparticles generates immunologic protection in a murine model of peanut allergy
K. Roy (1999)
Study of the inactivation process of the tetanus toxoid in contact with PLGA degrading microspheres
M Tobío (1998)
10.1016/S0378-5173(99)00178-7
Formulation strategies for the stabilization of tetanus toxoid in poly(lactide-co-glycolide) microspheres.
A. Sánchez (1999)
10.1016/S0168-3659(02)00363-2
Nasal drug delivery--possibilities, problems and solutions.
L. Illum (2003)
10.1023/A:1011063232257
Tetanus Toxoid Loaded Nanoparticles from Sulfobutylated Poly(Vinyl Alcohol)-Graft-Poly(Lactide-co-Glycolide): Evaluation of Antibody Response After Oral and Nasal Application in Mice
T. Jung (2004)
10.1089/0894268041457183
PEG-PLA nanoparticles as carriers for nasal vaccine delivery.
A. Vila (2004)
10.1002/PAT.280
PLA‐PEG nanospheres: new carriers for transmucosal delivery of proteins and plasmid DNA
A. Vila (2002)
Toxicity of chitosan
K Arai (1968)
10.1016/J.JCONREL.2004.04.026
Transport of PLA-PEG particles across the nasal mucosa: effect of particle size and PEG coating density.
A. Vila (2004)
10.1016/S0169-409X(01)00167-3
Microparticles for intranasal immunization.
M. Vajdy (2001)
10.1016/S0927-7765(99)00157-5
The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration.
Tobío (2000)
• Demonstrates the potential of chitosan nanosystems for nasal DNA vaccination
• Demonstrates the potential of chitosan powders for nasal vaccination in humans
10.1016/S0264-410X(00)00497-7
Immune responses to ISCOM formulations in animal and primate models.
A. Sjölander (2001)
10.3109/10611869909085514
Comparison of process parameters for microencapsulation of plasmid DNA in poly(D,L-lactic-co-glycolic) acid microspheres.
Y. Y. Hsu (1999)
Recent advances in vaccine
M Singh (2002)
10.1016/J.IJPHARM.2004.09.002
PLA-PEG particles as nasal protein carriers: the influence of the particle size.
A. Vila (2005)
10.1016/S0168-3659(01)00413-8
Hydrophilic poly(DL-lactide-co-glycolide) microspheres for the delivery of DNA to human-derived macrophages and dendritic cells.
E. Walter (2001)
Study of the inactivation process of the tetanus toxoid in contact with poly(lactic/glycolic acid) degrading microspheres
M. Tobío (1998)
10.1111/j.2042-7158.1993.tb05532.x
Immune Response to Nasal Delivery of Antigenically Intact Tetanus Toxoid Associated with Poly(l‐lactic acid) Microspheres in Rats, Rabbits and Guinea‐pigs
A. Almeida (1993)
10.1016/S0168-3659(98)00097-2
Chitosan and depolymerized chitosan oligomers as condensing carriers for in vivo plasmid delivery.
F. Maclaughlin (1998)
Websites 101 FDA Consumer magazine
Highlights the positive influence of a PEG coating for the transport of polyester nanoparticles across the nasal mucosa
10.1016/B978-0-08-031739-7.50009-4
IgA antibody-producing cells in peripheral blood after antigen ingestion: evidence for a common mucosal immune system in humans.
C. Czerkinsky (1987)
10.1023/A:1018820507379
A Novel System Based on a Poloxamer/ PLGA Blend as a Tetanus Toxoid Delivery Vehicle
M. Tobío (2004)
10.1016/S0168-3659(01)00486-2
Design of biodegradable particles for protein delivery.
A. Vila (2002)
10.1002/(SICI)1097-4628(19970103)63:1<125::AID-APP13>3.0.CO;2-4
Novel hydrophilic chitosan‐polyethylene oxide nanoparticles as protein carriers
P. Calvo (1997)
10.2165/00002018-200124140-00001
Technologies to Improve Immunisation Safety
C. J. Clements (2001)
10.1016/S0169-409X(01)00197-1
Chitosan for mucosal vaccination.
I. M. van der Lubben (2001)
World Healh Organization. State of the art of new vaccines
10.1023/A:1016444808000
Chitosans as Absorption Enhancers for Poorly Absorbable Drugs. 1: Influence of Molecular Weight and Degree of Acetylation on Drug Transport Across Human Intestinal Epithelial (Caco-2) Cells
N. G. Schipper (2004)
10.1016/0168-3659(95)00146-8
The potential of mucoadhesive polymers in enhancing intestinal peptide drug absorption. III: Effects of chitosan-glutamate and carbomer on epithelial tight junctions in vitro
G. Borchard (1996)
10.1016/S0169-409X(01)00171-5
Chitosan as a novel nasal delivery system for vaccines.
L. Illum (2001)
10.1016/S0264-410X(00)00248-6
Immune stimulating activity of two new chitosan containing adjuvant formulations.
P. Seferian (2000)
Stealth PLA–PEG nanoparticles as nasal protein delivery systems
M Tobio (1998)
10.1016/J.VACCINE.2004.03.033
Intranasal delivery of chitosan-DNA vaccine generates mucosal SIgA and anti-CVB3 protection.
W. Xu (2004)
10.1586/14760584.3.4.453
Antigen delivery systems
G. Kersten (2004)
10.1038/sj.gt.3301492
Chitosan as a nonviral gene delivery system. Structure–property relationships and characteristics compared with polyethylenimine in vitro and after lung administration in vivo
M. Köping-Höggård (2001)
10.1016/S0264-410X(02)00662-X
Nasal delivery of chitosan-DNA plasmid expressing epitopes of respiratory syncytial virus (RSV) induces protective CTL responses in BALB/c mice.
M. Iqbal (2003)
Highlights for the first time the potential of poly(lactide-co-glycolide) nanoparticles as carriers for nasal vaccine delivery
Biodegradable nanoparticles in nasal vaccine delivery: effect of particle size and loading
S Somavarapu (1998)
• Concludes that the uptake by and translocation from the intestinal mucosa of small particles is a normal occurrence
Design and characterisation of new nanoparticulate polymer blends for drug
N Csaba (2004)
10.1016/S0264-410X(01)00380-2
Tetanus toxin fragment C-specific priming by intranasal infection with recombinant Bordetella pertussis.
N. Reveneau (2001)
10.1016/0167-5699(92)90158-4
The role of nasopharyngeal lymphoid tissue.
C. Kuper (1992)
10.1016/J.ADDR.2004.09.004
Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery.
H. O. Alpar (2005)



This paper is referenced by
10.1080/10611860701637966
Rational design of nasal vaccines
B. Slütter (2008)
10.1016/j.jconrel.2009.02.010
Synthesis, characterization and evaluation of novel triblock copolymer based nanoparticles for vaccine delivery against hepatitis B.
A. K. Jain (2009)
10.1016/B978-0-323-35761-6.00066-3
66 – Technologies for Making New Vaccines
S. S. Ahmed (2018)
10.1016/J.EJPHAR.2005.12.068
Nanomedicine for respiratory diseases.
U. Pison (2006)
10.1016/j.vaccine.2011.04.112
Pharmaceutical and immunological evaluation of mucoadhesive nanoparticles based delivery system(s) administered intranasally.
S. Mangal (2011)
10.1016/J.IJPHARM.2007.03.025
Intranasal delivery: physicochemical and therapeutic aspects.
H. Costantino (2007)
Porous maltodextrin nanoparticles for the intranasal delivery of vaccines
B. Bernocchi (2016)
10.1007/s00106-019-00759-2
T-Zell-Immunreaktionen bei chronisch entzündlichen Erkrankungen der nasalen Schleimhäute
L. Klimek (2019)
10.3109/10717544.2014.908427
Mucoadhesive glycol chitosan nanoparticles for intranasal delivery of hepatitis B vaccine: enhancement of mucosal and systemic immune response
Dilip Pawar (2016)
10.1021/IE100307T
Nanocarrier Aided Nasal Vaccination: An Experimental and Computational Approach
Olga Kammona (2011)
Factores que intervienen en el diseño de sistemas de liberación nasal de péptidos y proteínas
A. Muñoz-Cernada (2013)
10.1016/j.msec.2012.12.002
Particle assemblies: toward new tools for regenerative medicine.
R. Roux (2013)
10.1016/j.ejpb.2010.12.001
Colloidal polyelectrolyte complexes of chitosan and dextran sulfate towards versatile nanocarriers of bioactive molecules.
T. Delair (2011)
10.1002/mabi.201100102
A potential nanomedicine consisting of heparin-loaded polysaccharide nanocarriers for the treatment of asthma.
F. Oyarzun-Ampuero (2012)
10.1016/j.vaccine.2010.06.121
Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen.
B. Slütter (2010)
10.1016/J.NANO.2006.11.008
The present and future of nanotechnology in human health care.
S. Sahoo (2007)
10.1016/j.ajps.2018.04.005
Preparation, characterization and in vivo evaluation of alginate-coated chitosan and trimethylchitosan nanoparticles loaded with PR8 influenza virus for nasal immunization
J. Mosafer (2019)
10.1016/j.ejps.2009.04.004
Quantifying drug release from PLGA nanoparticulates.
O. Corrigan (2009)
DEVELOPMENT AND CHARACTERIZATION OF BIPOLYMER BASED NANOPARTICULATE CARRIER SYSTEM AS VACCINE ADJUVANT FOR EFFECTIVE IMMUNIZATION
A. Verma (2013)
10.1002/jps.21493
Pharmaceutical aspects of intranasal delivery of vaccines using particulate systems.
S. Sharma (2009)
10.1002/JPS.20728
A practical approach to the use of nanoparticles for vaccine delivery.
J. Wendorf (2006)
10.1016/j.ejpb.2010.12.017
Relationship between the size of nanoparticles and their adjuvant activity: data from a study with an improved experimental design.
Xinran Li (2011)
10.1007/978-3-319-00978-0_18
Nasal Dry Powder Vaccine Delivery Technology
A. Hickey (2014)
10.1021/mp100390w
In vitro and in vivo mRNA delivery using lipid-enveloped pH-responsive polymer nanoparticles.
Xingfang Su (2011)
10.1517/17425247.3.4.463
The performance of nanocarriers for transmucosal drug delivery
N. Csaba (2006)
10.1016/j.ijpharm.2012.04.047
Vaccine delivery carriers: insights and future perspectives.
J. Correia-Pinto (2013)
10.1007/978-3-642-36853-0_4
Nanotechnological Approaches for Genetic Immunization
A. Goyal (2013)
10.1016/j.vaccine.2015.08.076
In vivo efficacy and toxicity evaluation of polycaprolactone nanoparticles and aluminum based admixture formulation as vaccine delivery system.
V. Bansal (2015)
10.1016/B978-0-323-39981-4.00010-5
Polymer-Based Nanoparticles as Modern Vaccine Delivery Systems
Laure Lambricht (2017)
10.1089/0894268041457183
PEG-PLA nanoparticles as carriers for nasal vaccine delivery.
A. Vila (2004)
10.1016/j.ijpharm.2014.05.061
Evaluation of synergistic effect of biodegradable polymeric nanoparticles and aluminum based adjuvant for improving vaccine efficacy.
V. Bansal (2014)
Factors involved in the design of nasal delivery systems for peptides and proteins
A. Muñoz-Cernada (2013)
See more
Semantic Scholar Logo Some data provided by SemanticScholar